Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent anti-hematological malignancies effects
Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases
The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies
